Literature DB >> 9488468

The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent.

L Whitesell1, P D Sutphin, E J Pulcini, J D Martinez, P H Cook.   

Abstract

Wild-type p53 is a short-lived protein which turns over very rapidly via selective proteolysis in the ubiquitin-proteasome pathway. Most p53 mutations, however, encode for protein products which display markedly increased intracellular levels and are associated with positive tumor-promoting activity. The mechanism by which mutation leads to impairment of ubiquitination and proteasome-mediated degradation is unknown, but it has been noted that many transforming p53 mutants are found in stable physical association with molecular chaperones of the hsp70 class. To explore a possible role for aberrant chaperone interactions in mediating the altered function of mutant p53 and its intracellular accumulation, we examined the chaperone proteins which physically associate with a temperature-sensitive murine p53 mutant. In lysate prepared from A1-5 cells grown under mutant temperature conditions, hsp70 coprecipitated with p53Val135 as previously reported by others, but in addition, other well-recognized elements of the cellular chaperone machinery, including hsp90, cyclophilin 40, and p23, were detected. Under temperature conditions favoring wild-type p53 conformation, the coprecipitation of chaperone proteins with p53 was lost in conjunction with the restoration of its transcriptional activating activity. Chaperone interactions similar to those demonstrated in A1-5 cells under mutant conditions were also detected in human breast cancer cells expressing two different hot-spot mutations. To examine the effect of directly disrupting chaperone interactions with mutant p53, we made use of geldanamycin (GA), a selective hsp90-binding agent which has been shown to alter the chaperone associations regulating the function of unliganded steroid receptors. GA treatment of cells altered heteroprotein complex formation with several different mutant p53 species. It increased p53 turnover and resulted in nuclear translocation of the protein in A1-5 cells. GA did not, however, appear to restore wild-type transcriptional activating activity to mutant p53 proteins in either A1-5 cells or human breast cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488468      PMCID: PMC108866          DOI: 10.1128/MCB.18.3.1517

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  A pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptor.

Authors:  S C Nair; E J Toran; R A Rimerman; S Hjermstad; T E Smithgall; D F Smith
Journal:  Cell Stress Chaperones       Date:  1996-12       Impact factor: 3.667

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.

Authors:  J Martinez; I Georgoff; J Martinez; A J Levine
Journal:  Genes Dev       Date:  1991-02       Impact factor: 11.361

4.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

Authors:  D Michalovitz; O Halevy; M Oren
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

5.  Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone.

Authors:  C Prodromou; S M Roe; R O'Brien; J E Ladbury; P W Piper; L H Pearl
Journal:  Cell       Date:  1997-07-11       Impact factor: 41.582

6.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

7.  Different tumor-derived p53 mutants exhibit distinct biological activities.

Authors:  O Halevy; D Michalovitz; M Oren
Journal:  Science       Date:  1990-10-05       Impact factor: 47.728

8.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

Authors:  P W Hinds; C A Finlay; R S Quartin; S J Baker; E R Fearon; B Vogelstein; A J Levine
Journal:  Cell Growth Differ       Date:  1990-12

9.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.

Authors:  A M Davidoff; J D Iglehart; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

10.  Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation.

Authors:  P Hainaut; J Milner
Journal:  EMBO J       Date:  1992-10       Impact factor: 11.598

View more
  63 in total

Review 1.  Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals.

Authors:  K A Morano; D J Thiele
Journal:  Gene Expr       Date:  1999

Review 2.  Hsp70 interactions with the p53 tumour suppressor protein.

Authors:  M Zylicz; F W King; A Wawrzynow
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

Review 3.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

4.  A set of proteins interacting with transcription factor Sp1 identified in a two-hybrid screening.

Authors:  M Gunther; M Laithier; O Brison
Journal:  Mol Cell Biochem       Date:  2000-07       Impact factor: 3.396

5.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Authors:  D Li; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

6.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

7.  Ubiquitination and degradation of mutant p53.

Authors:  Natalia Lukashchuk; Karen H Vousden
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

8.  Further characterization of BC3H1 myogenic cells reveals lack of p53 activity and underexpression of several p53 regulated and extracellular matrix-associated gene products.

Authors:  Sandra B Sharp; Maria Villalvazo; Mickey Huang; Rodolfo Gonzalez; Irania Alarcon; Matthew Bahamonde; Diane M D'Agostin; Sagar Damle; Alex Espinosa; Seog J Han; Jessica Liu; Paula Navarro; Hugo Salguero; Jina Son; Son Vu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002 Jul-Aug       Impact factor: 2.416

9.  TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

Authors:  Shinako Araki; Jacob A Eitel; Christopher N Batuello; Khadijeh Bijangi-Vishehsaraei; Xian-Jin Xie; David Danielpour; Karen E Pollok; David A Boothman; Lindsey D Mayo
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

10.  Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol.

Authors:  Gang Chen; Julie Izzo; Yusuke Demizu; Feng Wang; Sushovan Guha; Xifeng Wu; Mein-Chie Hung; Jaffer A Ajani; Peng Huang
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.